This report centers on our RNA targeting strategy as a starting point to develop drugs that can limit APP expression by a novel therapeutic mechanism for offsetting APP mRNA translation rates and reducing severe amyloidosis during the progression of DS and AD. The gene discussed is APP; the disease is Dravet syndrome.